Amyotrophic Lateral Sclerosis: Drug Therapy from the Bench to the Bedside

Summer Bell Gibson, M.D.1  Mark B. Bromberg, M.D., Ph.D.1

1 Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah


Abstract

Amyotrophic lateral sclerosis (ALS) is an unrelenting progressive neurodegenerative disease causing progressive weakness, ultimately leading to death. Despite aggressive research, the pathways leading to neuronal death are incompletely understood. Riluzole is the only drug clinically proven to enhance survival of ALS patients, but its mechanism of action is not clearly understood. In this article, the proposed pathophysiology of ALS is reviewed including glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, autoimmune mechanisms, protein aggregation, SOD1 accumulation, and neuronal death. Based on these mechanisms, past major ALS drug studies will be reviewed as well as promising current ALS drug studies, focusing on the advancement of these studies from the bench to the patient’s bedside.

Keywords ➤ amyotrophic lateral sclerosis ➤ ALS ➤ Lou Gehrig’s disease ➤ treatments and investigational drugs

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscular atrophy and weakness resulting from loss of both upper and lower motor neurons. It was first clinically and pathologically described by Charcot in 1874.1 Amyotrophic lateral sclerosis gained notoriety after the New York Yankee baseball player, Lou Gehrig, was diagnosed in 1939; to this day, it is commonly referred to as “Lou Gehrig’s disease” in the United States. The disease generally progresses rapidly and is inevitably fatal. The cause of death is relatively uniform—typically due to respiratory failure.2,3 The incidence ranges from 1.5 to 2.5 per 100,000 per year, with a lifetime risk of ~1:400.4 The mean age of onset is ~60 years, with a male predominance of 1.3:1. The median survival is 2 to 4 years from symptom onset, although a small percentage live longer than 10 years. The differential diagnosis is small and misdiagnosis is estimated to be less than 10%.6,7

Familial ALS is clinically indistinguishable from sporadic ALS. Familial ALS is generally defined as the history or presence of ALS in one or more 1st- or 2nd-degree family members of a person with ALS.8,9 The rate of familial ALS is 5 to 10%.9,10 In 1993, a superoxide dismutase (SOD1) mutation was discovered that can lead to ALS. Despite this advance, it was nearly a decade before the next gene mutation was discovered. There has recently been a rapid expansion in the number of recognized ALS mutations, with 10 different ALS mutations identified.10,11 It is estimated that the most common ALS genes, SOD1, TDP-43, and FUS mutations and the C9orf72 hexanucleotide repeat, account for 65% of familial ALS cases in the United States, although the percentage of ALS linked to these genes varies based on geographical region.12,13 For some of the genes, ALS is not the only neurodegenerative phenotype expressed. For example, the C9orf72 hexanucleotide repeat, is also a common cause of frontotemporal dementia (FTD), sometimes in combination with ALS, and sometimes in isolation with either ALS or FTD.12

There are currently >50 actively enrolling clinical trials for ALS listed on clinicaltrials.gov, with several times that number completed. Most drugs for ALS come through a traditional route of identifying a target and then screening for compounds that modify the activity of the target, then optimizing hits within the identified drug family to help select the ideal compound. However, drugs are increasingly coming from large screening efforts that examine compounds without known targets. This helps to identify potential drug treatments with mechanisms already known or thought to be related to ALS, but also identify potential drug treatments that cause reconsideration of the disease pathway. One of the first nontraditional screens for ALS and other selected neurologic diseases was the large community screening effort by...
the National Institute of Neurological Disorders and Stroke (NINDS) in the early 2000s. About 1,000 compounds were screened in a variety of biologic assays, the majority of which were already in use for nonneurologic diseases, and several had positive results. Here we will review proposed ALS disease mechanisms followed by historical and upcoming drug studies.

Disease Mechanisms

Although the exact cause of ALS is unknown, there are many theories that may represent a cascade of pathologic changes. An early and leading theory is that glutamate, the central nervous system’s most abundant excitatory neurotransmitter, causes neuron death when it is elevated, leading to the development of ALS. This was supported by a combination of findings in ALS patients including elevated glutamate levels found in fasting serum and cerebrospinal (CSF), a deficiency of leukocyte glutamate dehydrogenase, and defects in the glutamate transport system that lead to decreased clearance of extracellular glutamate. Oxidative stress is another prominent area of interest. The potential importance of antioxidant dysfunction was boosted with the discovery that SOD1 mutations cause familial ALS. SOD1 is a powerful antioxidant enzyme that catalyzes the dismutation of the highly reactive superoxide free radical generated in mitochondria, thus keeping it from harming cell structures. However, it is now believed that SOD1 mutations cause disease by a gain of function related to over-expression of the mutant SOD1 enzyme, leaving the role of antioxidant function in ALS less clear.

There is evidence supporting an autoimmune mechanism in ALS. It is hypothesized that the immune system targets the motor nerve terminal leading to a series of changes that alter calcium homeostasis. The disruption of calcium homeostasis may trigger neuronal cell death through apoptotic pathways. Additionally, the ALS SOD1 mouse model demonstrates increased inflammatory factors throughout its lifespan, including during presymptomatic stages. Macrophages, which play a key role in neuroinflammation, have been found at increased levels in spinal cord tissue of sporadic and familial ALS patients as well as in the ALS SOD1 mouse model.

The role of abnormal protein aggregation has been gaining support in neurodegenerative diseases including ALS. Proteins that may misfold in ALS include SOD1, TDP-43, and FUS. Cell-to-cell propagation of misfolded proteins may involve a prion-like phenomena. This basic finding may underlie the clinical observation of somatotopic spread of weakness in most ALS patients. Misfolded SOD1 proteins have been shown to induce the misfolding of normal wild type SOD1 in cell culture. This is supported by pathologic evidence that shows ALS begins focally and then spreads to neighboring neurons.

To facilitate the study of these hypotheses and to explore new treatments, animal models based on genetic mutations have been developed. SOD1 gene mutations were discovered before other ALS gene mutations and remain the most used and best described animal models. However, there is growing concern that the SOD1 animal model may not represent ALS as a whole. SOD1 mutations only cause ~2% of all ALS, and thus the mechanisms may be distinct from other forms of ALS.

To address this concern, particularly with drugs that target the SOD1 mutation, some ALS drug studies only include patients with known SOD1 mutations.

Stem Cell Therapy

ALS is an area of intense interest for stem cell transplant research. Unfortunately, many ALS patients have fallen prey to false promises and stem cell scams, both in the United States and abroad. Stem cell studies have yielded positive results in both in vitro and ALS animal models using a variety of different cell types. Mesenchymal stem cells (bone marrow derived) and neural progenitor cells (spinal cord-derived) are the two cell types with the most evidence for use in ALS. Both mesenchymal and neural progenitor cells have supporting data from SOD1 animal model studies, demonstrating improved survival, when compared with control animals. Mesenchymal stem cells have the advantage of autologous implantation, thus reducing rejection issues and the need for immunosuppressant therapy. However, recent studies show that mesenchymal cells isolated from ALS patients have reduced pluripotency and trophic factors and thus suggest a reduced potential for autologous mesenchymal transplants in ALS patients.

Antiglutamate Drugs

Riluzole was developed in the 1950s as a centrally acting muscle relaxant and later investigated as an antiseizure and a neuroprotective agent. The exact mechanism of action of riluzole is unknown, but it has multiple properties, including inhibition of sodium, calcium, potassium, and glutamate currents. In preclinical studies, riluzole was found to modulate the transmission of glutamate in hippocampal slices. After clinical studies in ALS, riluzole was approved by the Food and Drug Administration (FDA) in 1995 for treatment. The clinical benefits are modest, extending ventilator-free survival by ~3 months, but it remains the only FDA-approved disease-modifying drug for ALS.

Other antiglutamate drugs have been evaluated in clinical trials. Most are antiseizure medications that have antiglutamate properties, and include topiramate, gabapentin, and lamotrigine, but none have demonstrated survival benefit. Topiramate, a sugar derivative, has four main properties: inhibition of the enzyme voltage-dependent sodium channels, inhibition of carbonic anhydrase, enhancement of some GABA-A receptors, and antagonism of glutamate receptors. Initial topiramate studies with organotypic spinal cord culture were promising; however, it failed to improve survival in the ALS SOD1 mouse model. This was followed by a double-blind placebo-controlled, multicenter randomized clinical trial with 296 ALS patients. In this study, those treated with topiramate actually had a faster decline in upper-extremity strength than those treated with placebo, and it failed to result in increased survival, or change in the decline in
forced vital capacity (FVC) or the ALS Functional Rating Scale (ALSFRS). Gabapentin primarily works by inhibiting voltage-gated calcium channels, but at high doses reduces glutamate synthesis. When phase II and phase III results were combined, there was a significantly increased rate of decline in FVC in the gabapentin-treated group, and the studies failed to result in any improvement in survival or change in the rate of decline in ALSFRS or timed walk. Lamotrigine is a sodium channel blocker that also inhibits the release of glutamate and aspartate. Lamotrigine has been studied in two double-blind placebo controlled trials, the first at low dose (100 mg daily) and the second at a moderate dose (300 mg daily), but both studies failed to show any improvement in ambulation, bulbar symptoms, or ALSFRS. Other drugs with antiglutamate properties, including dextromethorphan and memantine, failed to show improvement in survival.

Despite these multiple negative studies, several antioxidant drugs show promise and are currently in development stages. Talampanel (LY300164), a benzodiazepine that is a noncompetitive AMPA antagonist with antiglutamate properties, has completed a phase II drug trial with 59 ALS patients. The results were mixed, but had promising aspects; the decline in muscle strength was slowed by 15% and the decline in the ALSFRS was slowed by 30% in the talampanel-treated group; nevertheless, neither measure reached statistical significance, and there was no survival benefit. In a recent SOD1 ALS mouse study with talampanel, motor neuron calcium levels were reduced, but only when given presymptomatically. Ceftriaxone, a third-generation cephalosporin, which likely modifies glutamate by altering the glutamate transport protein, is currently in a phase III trial, with 600 ALS participants. Glutamate carboxypeptidase II (NAALADase) has been proposed because of its dual antiglutamate mechanism, by directly decreasing production of glutamate and indirectly increasing the breakdown of glutamate in the central nervous system. Additionally, glutamate carboxypeptidase II has been shown to reduce neuroprotective changes in the ALS SOD1 mouse model.

Antioxidant/Mitochondrial Preservation Drugs

The first study of an antioxidant agent (vitamin E) for ALS was published in 1940. This study had several critical design flaws and remains an example of the need for controls and blinding. Included in the multiple vitamin E responders was Lou Gehrig himself, who reportedly “improved” with treatment. Despite continuing his treatment with high doses of oral and injected vitamin E, he passed away one year later. Interest in vitamin E was rekindled due to delayed disease onset in the ALS SOD1 mouse model. Two randomized controlled double-blind clinical studies of vitamin E or placebo in combination with riluzole have now been completed. One used 600 IU daily and the other 5,000 mg daily. Neither showed benefit on survival or functional status when vitamin E was added to riluzole. However, the issue remains open, as there have been recent studies suggesting a decreased ALS risk among long-term vitamin E users.

Other antioxidant agents and other drugs targeted to mitochondrial function have also been investigated. N-acetylcysteine, an over-the-counter antioxidant, significantly prolonged survival and delayed motor symptom onset when given presymptomatically in the ALS SOD1 mouse model. However, a clinical ALS trial with N-acetylcysteine failed to produce significant differences in survival or change in decline of motor symptoms. Creatine, which has neuroprotective effects, also had positive animal data, but the human ALS studies failed to show significant differences in survival, ALSFRS-revised (ALSFRS-R), or FVC in those treated with 5 to 10 g of creatine. The antidiabetes type II drug, metformin, with antioxidant and antiinflammatory properties, showed no benefit in male ALS SOD1 mice and accelerated disease progression in the female mice. There have been many other small studies with antioxidants, such as selegiline and melatonin, and though these failed to produce positive results they are generally too small to draw significant conclusions.

Despite multiple negative antioxidant drug trials, one agent remains promising. Dexpramipexole, the R enantiomer of pramipexole, has antioxidant effects, in part by targeting preservation of mitochondria function by reducing apoptosis. The S-enantiomer, pramipexole is currently used for Parkinson’s disease and restless leg syndrome. The pure R form has less dopaminergic receptor affinity and thus reduces many of the dose-limiting dopaminergic side-effects. Dexpramipexole is currently in phase II trials based on a promising two-part phase II trial, which showed a dose-dependent trend toward a slower decline in the ALSFRS-R and significant difference in decline of both mortality and ALSFRS-R.

Immunosuppressive Drugs and Procedures

Multiple immunosuppressive drugs have been studied, including corticosteroids, plasmapheresis, intravenous immunoglobulin, cyclophosphamide, and cyclosporine, all of which failed to alter disease progression. Minocycline is a tetracycline antibiotic that decreases inflammation by inhibiting microglial activation. SOD1 animal studies were optimistic, showing delayed disease onset, prolonged survival, and decreased motor neuron loss when given to presymptomatic animals. In phase I/II trials there were no major safety issues. In a phase III randomized placebo-controlled trial, those treated with minocycline had a significantly greater decline in the ALSFRS-R score. There was also a nonsignificant trend toward a faster decline in breathing function and muscle strength as well as mortality. These results were supported by experiments in the ALS SOD1 mouse model that showed when minocycline was given late in the symptomatic phase it no longer had a neuroprotective effect, but caused an increased inflammatory response.

A new investigational agent, NP001, targets another mechanism of neuroinflammation, by regulating macrophage activation and potentially returning macrophages back to their neuroprotective state. In the phase I study, patients were
given four doses of ascending quantity and ALS progression-associated biomarkers were measured. The drug was determined to be safe and tolerable at doses given. Additionally, ALS progression biomarkers levels had a statistically significant dose-dependent decrease to each of the NP001 treatments. NP001 is currently in a phase II study.

**Muscle-Maintenance Drugs**

Another proposed target for the drug treatment of ALS is at the muscle itself. CK-2017357 activates skeletal muscle by causing it to be more sensitive to calcium. By lowering the muscle sensitivity to calcium it is theorized to increase the force produced by the muscle stimulus. A double-blind randomized placebo-controlled phase II trial of CK-2017357 has been completed. Part A of the phase II trial included patients not taking riluzole, and part B included patients taking riluzole but at a reduced dose of 50 mg daily (instead of 50 mg twice a day). The treated patients had a dose-dependent improvement in maximum ventilation and handgrip endurance that trended toward significance.

**SOD1 Specific Treatments**

ISIS-SOD1rx is an antisense oligonucleotide that targets and reduces the synthesis of SOD1. It has been shown to prolong survival in symptomatic ALS SOD1 rats. Phase I trials to determine safety of ISIS-SOD1rx in familial ALS patients with a confirmed SOD1 mutation have been completed and the agent appears safe. Arimoclomol and pyrimethamine, both of which are currently in clinical trial, are also being tested in patients with SOD1 mutations. Arimoclomol, which is in phase II/III, has been shown to increase survival and improve motor function in the ALS SOD1 mouse model. Arimoclomol is believed to protect motor neurons from cell death by amplifying the cytoprotective heat shock response in times of stress. Pyrimethamine, an antimalarial and toxoplasmosis drug, has been found to reduce in vitro levels of SOD1 in mice and humans. It was identified as a potential SOD1 lowering agent through a high-throughput screen, and a phase I/II study is underway.

**Stem Cells**

The first stem cell trial for ALS surgically implanted autologous mesenchymal cells into the dorsal spinal cord of 19 ALS patients. This study has now completed a two-part phase I trial with long-term follow-up, and the treatment appears to be reasonably safe. The second mesenchymal safety study included both multiple sclerosis (MS) and ALS patients. Nineteen ALS patients had autologous enhanced mesenchymal cells injected intrathecally and intravenously. Patients were followed from 6 to 18 months and the procedure was felt to be reasonably safe. The first human controlled trial with neural stem cells (spinal cord derived cells) was safe in 12 patients. Although the study was not intended nor powered for efficacy, one subject had striking improvement in their ALSFRS-R score. Part 2 of phase 1 is underway with intraspinal injections in the cervical cord, with the goal of preferentially protecting respiratory motor neurons.

**Conclusion**

The race to understand and treat ALS is on. Despite aggressive research, riluzole remains the only FDA-approved pharmacological therapy for ALS. The myriad mechanisms of ALS pathophysiology discussed, including glutamate excitotoxicity, the role of antioxidants, mitochondrial dysfunction, autoimmune components, and protein aggregation, suggest that ALS is a complex disease for which we still know remarkably little. Although there have been positive results in pharmacologic targeting of all of the mechanisms discussed in this review, no agent has been developed that significantly alters the natural history. While curative drugs have been discovered in the past for other diseases without a complete understanding of the pathophysiology or all of the relevant targets, it is unlikely that major breakthroughs in ALS treatment will come without a more complete understanding of the true disease mechanism.

We eagerly await the phase III results of the antiglutamate drug ceftriaxone, and the mitochondria preservation drug, dexpamipexole. Given the multiple human studies that failed to confirm findings from animal studies, we are cautious about placing too much emphasis on the results from animal studies, particularly when completed in the asymptomatic phase.

**References**

13 Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011;7(11):603–615
26 Polyemidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011;147(3):498–508
31 The darker side of stem cells. Nature 2012;483(7387):5
65 Cheah BC, Kierman MC. Dexpramipexole, the R(+) enantiomer of pramiqepexole, for the potential treatment of amyotrophic lateral sclerosis. IDRs 2010;13(12):911–920
76 Keller AF, Gravel M, Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol 2011;228(1):69–79